Sein métastatique triple négatif ASCENT (IMMU-132-05) Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer. Paris, Saint-Cloud DELPHINE LOIRAT, FLORENCE LEREBOURS
Sein métastatique HER2+ DS8201-A-U301 (DESTINY- Breast02) A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1. Paris, Saint-Cloud
Sein métastatique HER2+ DS8201-A-U302 (DESTINY-Breast03) A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Paris, Saint-Cloud
Sein métastatique HER2+ PATINA A Phase III, Randomized, Open Label Trial to Evaluate the Efficiency and Safety of Palbociclib + AntiHER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Reception Positive (HR+)/HER2 Positive Metastatic Breast Cancer MBC-1 Paris, Saint-Cloud
Sein métastatique RH+ EMERALD ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL Paris, Saint-Cloud
Sein métastatique HER2+ EPIK-B2 (CBYL719G12301) Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Sein métastatique RH+ HerSeq (PUMA-NER-9501) HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for;Enrollment into Clinical Research Studies of Neratinib Paris, Saint-Cloud
Sein métastatique RH+ PALATINE - UC-0140/1814 ADVANCED BREAST CANCER: THERAPY INTEGRATING LOCOREGIONAL TREATMENT IN DE NOVO,;TREATMENT NAIVE, STAGE IV ER+, HER2- BREAST CANCER PATIENTS RECEIVING LETROZOLE AND;PALBOCICLIB Paris, Saint-Cloud
Appareil Digestif REGIRI (PRODIGE 58) A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas Paris, Saint-Cloud
Sein métastatique triple négatif EPIK-B3 (CBYL719H12301) A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation Paris, Saint-Cloud FLORENCE COUSSY, FLORENCE COUSSY